Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy.

To explore acute and late coronary outcomes and their risk/modifiers in patients with Kawasaki disease (KD).
Retrospective study.
1073 patients with KD identified from a tertiary care medical centre (1980-2012; 8677 patient-years).
The acute coronary severities and late outcomes (survival free of coronary aneurysm persistence and ischaemia) were assessed.
Coronary arterial lesions occurred in 40.6% of cases at their acute febrile stages, and persisted beyond 1 month in 196 (18.3%, M/F=138/58) patients: 125 (11.6%) had small aneurysms, 44 (4.1%) had medium aneurysms, and 27 (2.5%) had giant aneurysms. At follow-up (1-46 years), coronary aneurysms persisted in all with giant aneurysms, in 55% of those with medium aneurysms (18% with stenosis), and in 9% of those with small aneurysms. Ischaemia events occurred in 14 patients (M/F=13/1) and caused four deaths. Among the patients with KD with coronary aneurysms, 10-year ischaemia event-free and aneurysm persistence probability was 87.5% and 20.6%, respectively. The only independent risk for aneurysm persistence was the aneurysm severity 1 month after KD onset (χ(2)=80.73, p<10(-3)). Male patients and intravenous γ-immunoglobulin (IVIG) therapy were independent risk factors of initial coronary severity but were not associated with the late coronary outcomes, even in severity stratified subgroups.
The coronary severity 1 month after KD onset is most crucial to the late coronary outcomes. Although IVIG use improves the initial severity of coronary lesions, it does not further modify the long-term fate of coronary aneurysms.
AuthorsMing-Tai Lin, Li-Chuan Sun, En-Ting Wu, Jou-Kou Wang, Hung-Chi Lue, Mei-Hwan Wu
JournalArchives of disease in childhood (Arch Dis Child) Vol. 100 Issue 6 Pg. 542-7 (Jun 2015) ISSN: 1468-2044 [Electronic] England
PMID25564534 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Chemical References
  • Immunoglobulins, Intravenous
  • Aged
  • Coronary Artery Disease (drug therapy, etiology)
  • Coronary Vessels (pathology)
  • Female
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Male
  • Mucocutaneous Lymph Node Syndrome (complications, drug therapy)
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: